A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

This is a single center, Phase 1 study that utilizes a randomized, multiple-dose, double-blind, 5-way crossover design with a placebo control and two active controls. A minimum seven day washout period following four days of dosing for each of the five treatments.

Inclusion criteria

• Healthy subjects with no clinically significant findings note on screening assessments including medical history, physical examination and laboratory results

Exclusion criteria

• Clinically significant medical condition
• Clinically significant history of ECG abnormalities or family history of QTc interval syndrome
• Use of tobacco and/or nicotine products >3 months prior to screening
• Use of any prescription medications within 14 days prior to screening
• Use of over the counter medications (including herbal products) within 7 days prior to screening